Recent developments in oncology include Amgen’s FGFR2b-targeting antibody showing significant overall survival gains in a Phase 3 stomach cancer trial, albeit with ocular side effects raising concerns. Additionally, Actinium Pharmaceuticals’ ATNM-400, an Ac-225 radioconjugate targeting a PSMA-family antigen, demonstrated superior efficacy in prostate cancer. Vitsgen Therapeutics introduced a PSMA-targeted radiotheranostic [177Lu]PSMA-VG-01 for metastatic castration-resistant prostate cancer. These innovations signify growing precision medicine approaches targeting novel cancer antigens and combining diagnostics with therapy.